PremiumRatingsAnnexon Biosciences: Promising Growth Potential with Key Catalysts and Strategic FDA Interactions Annexon Biosciences: Buy Rating Driven by Regulatory Milestones and Promising Pipeline Developments Annexon Biosciences Reports Increased Q1 2025 Losses PremiumThe FlyNeedham healthcare analysts hold analyst/industry conference call Biotech Alert: Searches spiking for these stocks today Biotech Alert: Searches spiking for these stocks today PremiumRatingsPromising Potential of Annexon Biosciences’ ANX1502 Drives Buy Rating Amid Positive Clinical Data Annexon price target lowered to $20 from $30 at H.C. Wainwright Strategic Advancements and Financial Stability Drive Buy Rating for Annexon Biosciences 
